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Abstract
This study was focused on whether or not isoflavones affect the increase in bone mineral density of growing females. Female Sprague-Dawley
rats (60 ± 5 g) were randomly assigned to two groups and provided control diets (control group) or isoflavone-supplemented diet (IF group, 57.8
mg isoflavones/100 g diet) for 9 weeks in growing female rats. Measurements of Bone Mineral Density (BMD) and Bone Mineral Content (BMC) 
on the experimental animals were executed in the 3
rd, 6
th, 9
th weeks. In result, there was no significant difference in spine BMD between the isoflavones
supplemented group and the control group. But, the IF group tended to have higher BMD than the control group in between 3 and 9 experimental
weeks, and the striking difference could be shown in the 6
th week of feeding. In case of femur BMD, the effects of added isoflavones appeared
in the 6
th week of feeding, and it became intensified in the 9
th week of feeding to the extent that the BMD in the IF group was significantly
higher than that of the control group (p<0.05). In conclusion, isoflavone supplementation increased spine BMD per weight in the 6
th week of feeding,
and affected the increase of femur BMD in the 9
th week. The result of the experiment implies that it affects positively the formation of spine 
and femur BMD of growing female rats. The study also suggests that the effects of isoflavone on the pattern of BMD formation might differ
from the parts of bones. 
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Introduction3)
Epidemiological studies suggest that the low incidence of 
osteoporosis and
  heart diseases caused by estrogen deficiency 
in Asian women
  is attributable to their high intake of soy foods, 
compared with
  American and Finnish women (Adlercreutz et al., 
1992; Anderson et al., 1995; Brandi, 1997). It is reported that 
dietary
  soybean proteins prevent bone loss in ovariectomized 
(OVX) rats
  (Arjmandi et al., 1996). Possible candidates for the 
beneficial substances present
  in soybeans are isoflavones, such 
as genistein and daidzein (Ishimi et al., 1999). Isoflavones are 
estrogen-like
  substances structurally and functionally similar to 
17 β-estradiol (Knight & Eden, 1996). On the basis of evidence 
primarily from animal and in vitro
  studies, isoflavones are 
thought to exert both estrogenic and
  antiestrogenic effects, 
depending on the tissue in which they
  act (Makela et al., 1994). 
Isoflavones may exert a weak antagonistic effect on
  the estrogen 
receptor (Makela et al., 1994), thereby having an antiestrogenic
 
effect on uterine and breast tissue (Santell et al., 1994), where 
excess estrogen
  may stimulate synthesis. Alternatively, isofl-
avones may combine
  with the estrogen receptor, albeit with lower 
affinity than
  17  β-estradiol (Miksicek, 1994), and stimulate 
estrogen activity, thus
  having an estrogenic effect on bone 
(Makela et al., 1994) and blood vessels (Schonherr et al., 1997). 
Recent studies (Eriksen et al., 1998; Oursler et al., 1991) have 
shown that phytoestrogen has a higher binding affinity to 
estrogen receptor-β than to estrogen receptor-α. It is suggested 
that the possibility of isoflavones having a tissue-selective effect 
is high, since isoflavones may function more selectively on such 
organs as the thyroid gland, bones and blood vessels, where 
estrogen receptor-β is highly dispersed (Kuiper et al., 1998 ).
Some in vitro studies have suggested that isoflavones may have 
anti-estrogenic effects and estrogenic effects at the same time 
(Jayagopal et al., 2002; Lees & Ginn, 1998). The studies report 
that isoflavones may not be good for growing and young women, 
for they would reduce the activation of endogenous estrogen 
(Jayagopal  et al., 2002). 
On the contrary, according to some recent studies, isoflavone 
intake in infancy through soy-based infant formulas may have 
positive effects in the long term, as it may prevent hormone- 
dependent diseases such as cancer, osteoporosis, cardiovascular 
diseases, etc. that can be developed in the latter part of adulthood 
(Setchel et al., 1998). Disputes over the theory still remain 
unsettled, though. There is no concrete result on whether or not 
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Table 1. Composition of experimental diets (g/kg of diet) 
Groups
Ingredients Control IF (Isoflavones)
Casein
1) 200 200
Corn starch 530 528.2
Sucrose 100 100
Soybean oil 70 70
Cellulose 50 50
Min-mix
2) 35 35
Vit-mix
3) 10 10
L-cystine 3 3
Choline 2.5 2.5
Tert-butyl hydroquinone 0.014 0.014
Isovon
4) -1 . 8
1) Casein high p rotein (total p rotein 85% ), Teklad  Test D iets, M adison, Wisconsin, 
USA 
2) AIN-93G-MX,  Teklad  Test  Diets,  Madison,  Wisconsin,  USA 
3) AIN-93G-VM,  Teklad  Test  Diets,  Madison,  Wisconsin,  USA 
4) Isoflavones  compound:  Isovon  (total  isoflavones  32%),  Pacific  Chemical,  Korea 
Table 2. Effects of isoflavone supplementation on weight gains, mean food 
Intake and food intake efficiency ratio (FER) in growing female rats 
Group Control IF p value
4)
Weight gains (g)
1) 156.4 ± 22.11
3) 159.4 ± 18.00 NS
Mean food intake (g/day) 13.94 ± 0.72 13.62 ± 1.19 NS
FER
2)  0.18 ± 0.02   0.18 ± 0.01 NS
1) Total  body  Weight  gains  for  9  weeks 
2) Food  intake  efficiency  ratio  (FER)
3) Mean ± SD 
4) Value  is  based  on  t-test  analysis,  p<0.05.
the isoflavones found in soy protein cause a decline in bone 
density, or osteoporosis. There is little evidence of the 
mechanism, either. Since most previous studies on isoflavones 
focused on the features and effects of isoflavones that are similar 
to those of estrogen, the target of the experiments were pre- or 
post-menopausal women and ovariectomized animals. 
It has been rarely studied if isoflavones have positive or negative 
effects on growing and young women. Whatever studies have 
been conducted has shown no significant results yet. The most 
important risk factor of the occurrence of osteoporosis is low 
peak bone mass and rapid rates of bone loss. As such, mitigation 
of the risk of fracture is dependent on an increase in the peak 
bone mass and thereafter, on minimization of bone loss. 
This study was focused on whether or not isoflavones- 
supplementation affects the increase in bone mineral density of 
growing females. To examine the effects of isoflavones, we 
provided isoflavone which is extracted from soy for 9 weeks 
to growing female rats.
Materials and Methods 
Experimental animals and diets 
Female Sprague-Dawley rats (60 ± 5 g) were bought from 
KLEC (Korea Life Engineering Co., Seoul, Korea). Rats were 
fed stock diets (rat chow made by Samyangsa) for a week of 
adaptation period. Then, they were randomly divided into two 
experimental dietary groups, which included 12 rats each, and 
provided experimental diets for 9 weeks. 
All experimental rats were individually housed in stainless steel 
wired cage in an air-conditioned room with controlled temp-
erature (25 ± 2℃) and humidity (63 ± 5%) and automatic lighting 
(alternation 12-h period of light and dark). The experimental diet 
and deionized water were provided ad libitum. 
The experimental groups were divided into control group and 
isoflavone supplemented group (IF). The diets were formulated 
based on AIN-93G (Reeves et al., 1993). The two groups were 
based on same composition, but the diet of IF group was provided 
with isoflavones, extracted from soybean. The amount of 
isoflavone supplemented into experimental diet was 57.8 mg /100 g 
diet. The composition of experimental diets is shown in Table 1. 
The analysis of the experiment 
Measurement of the amount of dietary intake and the weight 
gains 
During the experiment period, the amount of dietary intake 
was measured once every other day and the weight of 
experimental animals, once a week at a specific time. 
Measurement of bone mineral density
Measurements of bone mineral density (BMD) and bone 
mineral content (BMC) on the experimental animals were 
executed in the 3
rd, 6
th, 9
th weeks. After the rats received 
intramuscular injection (75 mg/kg) with ketamine hydrochloride 
(Yuhan Kimberly, 50 mg/ml), their BMD and BMC in their spine 
and femur were measured with PIXImus, which is specialized 
for small animal, and with Dual energy x-ray absorptiometry 
(DEXA) made by GE, LUNAR (Madison, WI, USA). The unit 
of BMC is gram (g), and that of BMD is gram per square 
centimeter (g/cm
2).
Statistical analysis
Statistical analysis was conducted using the SAS program 
(Statisical Analysis System 9.13 version, SAS Institute Inc. Cary, 
NC). The mean and standard deviation were calculated for all 
the variables, statistical significance between the groups was 
tested by t-test. Differences were considerd significant at p<0.05. 
Results 
Effects on weight gains, mean food intake and food intake 
efficiency
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Table 3. Effects of isoflavone supplementation on spine bone mineral density (BMD) and bone mineral content (BMC) after 3, 6 and 9 weeks of feeding 
Group Control IF P value
2) Group Control IF P value
3 weeks
Spine BMD (g/cm
2) 0.0992 ± 0.0077
1) 0.0959 ± 0.0098 NS Spine  BMD/wt  (g/cm
2/kg) 0.57 ± 0.03 0.59 ± 0.06 NS
Spine BMC (g) 0.2107 ± 0.0284 0.2183 ± 0.0240 NS Spine BMC/wt (g/kg) 1.20 ± 0.22 1.40 ± 0.17 NS
6 weeks
Spine BMD (g/cm
2) 0.1247 ± 0.0105 0.1292 ± 0.0501 NS Spine  BMD/wt  (g/cm
2/kg) 0.57 ± 0.01 0.62 ± 0.03 <0.05
Spine BMC (g) 0.3380 ± 0.0194 0.3510 ± 0.0395 NS Spine BMC/wt (g/kg) 1.56 ± 0.08 1.70 ± 0.17 NS
9 weeks
Spin BMD (g/cm
2) 0.1469 ± 0.0082 0.1481 ± 0.0101 NS Spine  BMD/wt  (g/cm
2/kg) 0.61 ± 0.07 0.64 ± 0.05 NS
Spin BMC (g) 0.4351 ± 0.0399 0.4516 ± 0.0380 NS Spine BMC/wt (g/kg) 1.84 ± 0.16 1.95 ± 0.16 NS
1) Mean ± SD 
2) Value  is  based  on  t-test  analysis,  p<0.05.
Table 4. Effects of isoflavone supplementation on femur bone mineral density (BMD) and bone mineral content (BMC) after 3, 6 and 9 weeks of feeding 
Group Control IF P value
2) Group Control IF P value
3 weeks
Femur BMD (g/cm
2) 0.1336 ± 0.0078
1) 0.1307 ± 0.0083 NS Femur BMD/wt (g/cm
2/kg) 0.76 ± 0.06 0.82 ± 0.06 NS
Femur BMC (g) 0.1960 ± 0.0194 0.1906 ± 0.0168 NS Femur BMC/wt (g/kg) 1.21 ± 0.03 1.11 ± 0.11 <0.05
6 weeks
Femur BMD (g/cm
2) 0. 1791 ± 0.0095 0. 1812 ± 0.0062 NS Femur BMD/wt (g/cm
2/kg) 0.83 ± 0.04 0.83 ± 0.04 NS
Femur BMC (g) 0.3031 ± 0.0126 0.2877 ± 0.0156 NS Femur BMC/wt (g/kg) 1.40 ± 0.10 1.38 ± 0.05 NS
9 weeks
Femur BMD (g/cm
2) 0.2004 ± 0.0085 0.2064 ± 0.0112
a <0.05 Femur BMD/wt (g/cm
2/kg) 0.82 ± 0.03 0.89 ± 0.07 <0.05
Femur BMC (g) 0.3607 ± 0.0258 0.3795 ± 0.0273 NS Femur BMC/wt (g/kg) 1.52 ± 0.12 1.64 ± 0.04 <0.05
1) Mean ± SD 
2) Value  is  based  on  t-test  analysis,  p<0.05.
ratio (FER) observed for 9 weeks are shown in Table 2. 
Supplements of isoflavones had no significant effects on weight 
gains, mean food intake, and FER. 
Effects on bone mineral density
Spine BMD & BMC and Spine BMD & BMC per weight after 
3, 6 and 9 weeks of feeding
After 3, 6 and 9 weeks of feeding experimental diets, the results 
of spine BMD, BMC, BMD per weight, and BMC per weight 
are shown in Table 3. There was no significant difference 
between control group and IF group in spine BMD and BMD 
per weight after 3 weeks of feeding. The results of BMC and 
BMC per weight were not significantly different between control 
and IF groups in the 3
th week. 
After 6 weeks of feeding, as spine BMD in control group was 
0.1247 g/cm
2, and IF group was 0.1292 g/cm
2, there was no 
significant difference between the two groups. The amount of 
spine BMD increase was 0.0255 g/cm
2 in the control group and 
0.0333 g/cm
2 in IF group between the 3
rd and 6
th weeks of 
feeding, showing that IF group showed 30.6% more increase than 
control group. 
Spine BMD per weight in IF group (0.62 g/cm
2/kg) was 
significantly higher than that in control group (0.57 g/cm
2/kg). 
The difference between groups was 8.8%, and it has significant 
meaning. This indicates much higher increase in IF group than 
in control group. Spine BMC between the two groups had no 
significant difference in the 6
th week. The increase in spine BMC 
between 3
rd week and 6
th week was 0.1273 g in the control group 
and 0.1327 g in the IF group. Spine BMC per weight of IF group 
was 8.9% higher than control group in the 6
th week, but it was 
not significantly different.
After 9 weeks of feeding, there was no significant difference 
between control group (0.1469 g/cm
2) and IF group (0.1481 
g/cm
2) in spine BMD. Spine BMC in the 9
th week was 0.4351 
g in control group and 0.4516 g in IF group respectively and 
the data showed no significant difference. In the 9
th week, there 
was no significant difference between groups in BMD and BMC 
per weight, but IF group tended to have higher figures than 
control group.
Femur BMD & BMC and Spine BMD & BMC per weight after 
3, 6 and 9 weeks of feeding
After 3, 6 and 9 weeks of feeding experimental diets, the results 
of femur BMD, BMC, BMD per weight and BMC per weight 
are shown in Table 4. After 3 weeks of feeding, femur BMD 
was 0.1336 g/cm
2 in control group and 0.1307 g/cm
2 in IF group 
respectively. It showed no significant difference. Femur BMC 
with adding isoflavone in the period indicated no difference as 
well. Femur BMD per weight after 3 weeks of feeding between 
groups showed no significant difference, but BMC per weight 
in IF group was significantly lower than that in control group.
After 6 weeks of feeding, femur BMD was not significantly 
different between control group (0.1791 g/cm
2) and IF group 
(0.1812 g/cm
2). However, the amount of growth on femur BMD 
growth was 0.0456 g/cm
2 in the control group and 0.0505 g/cm
2 
in IF group between the 3
rd and 6
th weeks of feeding, showing 
that IF group had 10.7% more growth than control group. Femur 
BMC in the two groups indicated no significant difference in 
the 6
th weeks of feeding. After 6 weeks of feeding, femur BMD 
per weight and femur BMC per weight in this period showed 
no significant difference.
Different from the results of the 3
rd and 6
th weeks, the femur 
BMD of IF group was significantly higher than that of control 
group after 9 weeks. Femur BMD per weight of IF group was 
0.89 g/cm
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group. Femur BMC measured after 9 weeks as well, in IF group 
had higher figures than control group, but there was no significant 
difference. Tendency of femur BMC in IF group was lower than 
that of control group in the 3
rd and 6
th weeks, but the former 
became higher than the latter in the 9
th week. The amount of 
growth on femur BMC was 0.1647 g/cm
2 in the control group 
and 0.1889 g in IF group between the 3
rd and 9
th weeks of feeding, 
showing that IF group had 14.7% more increase than control 
group. In the 9
th week of feeding, Femur BMC per weight of 
IF group was significantly higher than that in control group as well. 
Discussion
In this study, isoflavones had no significant effects on weight 
gains, mean food intake, and FER. In previous studies (Choi & 
Cho, 2003), both soy isolate and soy concentrate groups showed 
significantly lower in FER than casein group. This indicates that 
there is no difference in FER according to isoflavone intake 
groups but varies according to protein sources.
In this study, the spine BMD of control group showed 0.0992 
g/cm
2 (3
rd weeks), 0.1247 g/cm
2 (6
th weeks), and 0.1469 g/cm
2 
(9
th weeks). The spine BMD in male rats of similar weeks of 
ages was reported 0.15 g/cm
2  in the study of Chae (2002). The 
result is much similar to that of this study, 0.1469 g/cm
2. This 
study observed how and how much soy protein which contains 
high isoflavones and isoflavones itself affected spine BMD and 
BMC in the growing female rats. One of our findings are that 
the increased rate of spine BMD in the week of 3 to 6 was 
much higher than in the week of 6 to 9 after feeding.
Especially, spine BMD increase of the IF group in the week 
3 to 6 (0.0302 g/ cm
2) was 37.4% more than that in the week 
6 to 9 (0.0189 g/cm
2). In general, SD species white rats ovulate 
regularly after 8 weeks of age and secrete estrogen stably after 
13 weeks of age. In regarding this, since the secretion of estrogen 
was relatively low in between the 3
rd week of experiment (8~9 
weeks of age) and the 6
th week of experiment (11~12 weeks 
of age), the effects of isoflavones can be effective in spine that 
has more trabecula bone than femur. According to the previous 
study (Choi & Cho, 2003) that reported the effects of soy protein 
on the BMD of growing female rats by adding same amounts 
of isoflavones as in this study, the spine BMD in the 
isoflavones-supplemented group in the 3
rd week of experiment 
was significantly higher than that of casein group. The result 
of the former group was significantly higher in the 6
th week as 
well, but not statistically significant in the 9
th week.
The pattern of increasing spine BMD is similar to the previous 
study that supplemented isoflavones-abundant soy protein, but 
the extent of the effects on spine BMD increase is not identical. 
Isoflavones-abundant soy protein affected the increase of spine 
BMD than extracted isoflavones did, and the difference with the 
control group was bigger. Considering IF group affects spine 
BMD relatively weak, the isoflavones effect on spine BMD 
seems not only by isoflavones itself.
Compared this study with previous animal studies on the level 
of BMD, which measured by PIXImus on male rats of similar 
weeks of ages in this study, the result of femur BMD was 0.23 
g/cm
2  and BMC was 0.54 g (Chae, 2002). The level is somewhat 
higher than those of this study measured on female rats. Femur 
BMD and BMC measured by DEXA on male rats in 4 weeks 
of age were reported as 0.25-0.26 g/cm
2 and 0.37-0.49 g, 
respectively. Griffin et al. (1993) reported that the femur BMD 
of the SD species white rats in 2~8 weeks of age was 0.30～0.32 
g/cm
2. With regard to those results, BMD of the experimental 
animals mostly relies on the week of ages of the samples and 
the kinds of measurements.
The study observed periodically, classified by diet, the effects 
of isoflavones-abundant soy protein and isoflavones on femur 
BMD and BMC in growing age. The femur BMD in the 3
rd and 
6
th week had no significant difference between the two groups. 
In the 9
th weeks of feeding, since the increase rate of femur BMD 
had become higher, IF group tended to have bigger femur BMD 
than other groups. However, the increase of BMD in IF group 
became much higher after 9 weeks of feeding, and the difference 
from control group becomes significant. between the 3
rd and 9
th 
weeks of feeding.
The growth patterns of spine BMD and femur BMD in the 
9
th weeks of feeding have some differences. While the difference 
between the two experimental groups in spine BMD was not 
significant, IF group in the 3
rd and 9
th weeks of feeding tended 
to have higher level, and the gap between the two groups was 
the biggest in the 6
th week of feeding. In case of femur BMD, 
the effects of isoflavones supplementing appeared in the 6
th 
weeks of feeding, and the effects was intensified in the 9
th weeks 
of feeding to the extent that femur BMD in the IF group became 
significantly higher than that in the control group. As a result, 
the effects of isoflavones on BMD were different according to 
bone parts. The diet effects of the extracted isoflavones from 
soybean tend to come out earlier in spine that has more plentiful 
of trabecula bone than femur. Compared with cortical bone, 
trabecula bone has more active metabolism, so easily affected 
by metabolism (Pruitrt et al., 1992). Spine has more trabecula 
bone than cortical bone, while femur contains cortical bone more 
than 3 times than that of spine. That is why spine that has more 
trabecula bone is affected earlier than femur by isoflavones diet. 
Similar result was reported in the previous study(Choi & Cho, 
2003) that provided soy isolate with rich isoflavones for growing 
female rats as well. It is also similar to the changing patterns 
in spine and femur between the previous study and this study.
The effects of soy isoflavones diet are also changed according 
to the period of diet intake. Previous epidemiological research 
showed that current diet amount of soy isoflavones affects spine 
BMD, but does not femoral neck and trochanter. On the other 
hand, the whole life diet amount of it significantly affects femoral 
neck, but not significantly affects spine, even though as diet 
amounts increase as the spine BMD high. However, since the 72 Effects of isoflavone supplementation on the bone mineral density
study has reported that it does not affect trochanter, we can imply 
that same period of diet even its effects vary with regard to the 
bone parts (Rice, 1999).
Isoflavones’ effect of protecting bone on pre-menopausal 
women who have enough estrogen varies to authors. Ho et al 
who has studied Hong Kong-resident Chinese women reported 
that diets of soybean for pre-menopausal women in the age of 
30~40 brought about significant effect on spine BMD. 
Meanwhile, a massive size of epidemiological research on 
Chinese females in the age of 18~86 showed contrary results 
(Mei  et al., 2001). The study reported that isoflavones diet 
affected BMD for post-menopausal women, but it had little to 
do with pre-menopausal women. Greendale et al. (2002) who 
studied Asian American women presented that genistein diets 
affected spine and femur BMD for pre-menopausal women, but 
no relevance to post-menopausal women.
Comparing with other study results might be difficult, since 
there are not much previous studies on growing female rats. But 
there are some relevant studies. Providing growing male rats with 
soy protein that contains isoflavones increased calcium efficiency 
on spine and femur BMD to a higher level than casein group 
(Jung, 1995). It is also reported that supplementing casein diet 
group of the growing male rats with isoflavones increases spine 
and femur BMD per weight level (Chae, 2002). It implies that 
soy protein or isoflavones should be beneficial to bone. A 
previous study (Choi & Cho, 2003) reported that isoflavones-rich 
soy protein should be beneficial to the formation of spine and 
femur BMD on growing female rats. 
In summary, there was no significant difference in spine BMD 
between the IF group and the control group. But the IF group 
tended to have higher BMD than the control group in 6
th  week 
and 9
th week of feeding and the striking difference could be 
shown in the 6
th week of feeding. Spine BMD increase of the 
IF group in the week 3 to 6 after feeding was 37.4% more than 
that in the week 6 to 9 after feeding. In femur BMD, the effects 
of adding isoflavones appeared in the 6
th week of feeding, and 
it became intensified in the 9
th week of feeding to the extent 
that the BMD in the IF group was significantly higher than that 
of the control group (p<0.05). 
In conclusion, isoflavone supplementation increased spine 
BMD per weight in the 6
th week of feeding, and affected the 
increase of femur BMD in the 9
th week. The result of the 
experiment implies that it affects positively the formation of spine 
and femur BMD of growing female rats. The study also can 
suggest that the effects of isoflavone on the pattern of BMD 
formation might differ from the parts of bones. 
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